Mar 21 |
Relmada Therapeutics: Run Up Into Results May Resume Following This Drop
|
Mar 20 |
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q4 2023 Earnings Call Transcript
|
Mar 20 |
Q4 2023 Relmada Therapeutics Inc Earnings Call
|
Mar 19 |
Relmada Therapeutics, Inc. (RLMD) Q4 2023 Earnings Call Transcript
|
Mar 19 |
Relmada Therapeutics Inc Reports Full-Year and Q4 2023 Financial Results
|
Mar 19 |
Recap: Relmada Therapeutics Q4 Earnings
|
Mar 19 |
Relmada Therapeutics GAAP EPS of -$0.84
|
Mar 19 |
Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
|
Mar 18 |
Relmada Therapeutics FY 2023 Earnings Preview
|
Mar 12 |
Relmada Therapeutics to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Conference Call and Webcast on March 19, 2024
|